A new international consensus effort established detailed guidance on delivering CPX-351, the liposomal formulation of cytarabine and daunorubicin, outside inpatient hospital wards for therapy-related AML and AML with myelodysplasia-related changes. Published in Annals of Hematology, the recommendations focus on safe outpatient administration practices. The publication responds to operational bottlenecks in intensive leukemia care, where inpatient capacity and treatment logistics can limit patient access and throughput. For clinicians and health systems, the guidance provides a pathway to standardize outpatient protocols around monitoring, supportive care, and escalation criteria. For developers and payers, the move can influence design of future trials and real-world implementation models that treat intensive regimens as system-level processes rather than strictly inpatient events.